Deferiprone

Active ingredient: Deferiprone

In short: Deferiprone tablets are indicated for the treatment of transfusional iron overload in adult patients with thalassemia syndromes when current chelation therapy is inadequate. Limitations of Use Safety and effectiveness have not been established for the treatment of transfusional iron overload in pati

Forms & strengthsTablets (three times a day): 1,000 mg are white, film-coated, oval shaped tablets; imprinted with "T" score "1 K" on one side and plain on the other side. …
LabelAvKARE
Label updatedAug 14, 2026

What is Deferiprone used for?

Deferiprone tablets are indicated for the treatment of transfusional iron overload in adult patients with thalassemia syndromes when current chelation therapy is inadequate.

Limitations of Use

Safety and effectiveness have not been established for the treatment of transfusional iron overload in patients with myelodysplastic syndrome or in patients with Diamond Blackfan anemia.

Pediatric use information is approved for Chiesi USA, Inc.'s FERRIPROX

®(deferiprone) tablets. However, due to Chiesi USA, Inc.'s marketing exclusivity rights, this drug product is not labeled with that information.

âš  Boxed warning (FDA's strongest warning)

Deferiprone can cause agranulocytosis that can lead to serious infections and death. Neutropenia may precede the development of agranulocytosis.

Measure the absolute neutrophil count (ANC) before starting deferiprone therapy and monitor regularly while on therapy.

Interrupt deferiprone therapy if neutropenia develops.

Interrupt deferiprone if infection develops, and monitor the ANC more frequently.

Advise patients taking deferiprone to report immediately any symptoms indicative of infection.

Deferiprone dosage

Deferiprone tablets are available in a 1,000 mg formulation and a 500 mg formulation, which have different oral dosing regimens to achieve the same total daily dosage.

Deferiprone tablets (three times a day) - 1,000 mg - given three times a day

Deferiprone tablets - 500 mg - given three times a day

To prevent medication errors, before prescribing and dispensing, ensure that the tablet formulation is appropriate for the dosing regimen. Each tablet has distinct identifying characteristics

.

For patients who have trouble swallowing tablets, consider the use of oral solution .

Monitoring for Safety

Due to the risk of agranulocytosis, monitor ANC before and during deferiprone therapy.

Test ANC prior to start of deferiprone therapy and monitor on the following schedule during treatment:

First six months of therapy: Monitor ANC weekly;

Next six months of therapy: Monitor ANC once every two weeks;

After one year of therapy: Monitor ANC every two to four weeks (or at the patient's blood transfusion interval in patients that have not experienced an interruption due to any decrease in ANC

.

Due to the risk of hepatic transaminase elevations, monitor ALT before and monthly during deferiprone therapy

.

Due to the risk of zinc deficiency, monitor zinc levels before and regularly during deferiprone therapy

.

Starting Dosage for Three Times a Day Tablets

The recommended starting oral dosage of deferiprone tablets (three times a day) is 75 mg/kg/day (actual body weight), in three divided doses per day. Table 3 describes the number of deferiprone tablets (three times a day) needed to achieve the 75 mg/kg/day total starting dosage). Round dose to the nearest 500 mg (half-tablet).

Body Weight

(kg) | Morning | Midday | Evening

20 | 0.5 | 0.5 | 0.5

30 | 1 | 0.5 | 1

40 | 1 | 1 | 1

50 | 1.5 | 1 | 1.5

60 | 1.5 | 1.5 | 1.5

70 | 2 | 1.5 | 2

80 | 2 | 2 | 2

90 | 2.5 | 2 | 2.5

To minimize gastrointestinal upset when first starting therapy, dosing can start at 45 mg/kg/day and increase weekly by 15 mg/kg/day increments until the full prescribed dose is achieved.

Dosage Adjustments for Three Times Daily Tablets

Tailor dosage adjustments for deferiprone tablets (three times a day) to the individual patient's response and therapeutic goals (maintenance or reduction of body iron burden). The maximum oral dosage is 99 mg/kg/day (actual body weight), in three divided doses per day. Table 4 describes the number of deferiprone tablets (three times a day) needed to achieve the 99 mg/day total maximum daily dosage. …

How to take Deferiprone — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Medication Guide)

Instruct patients and their caregivers to store deferiprone at 68°F to 77°F (20°C to 25°C) .

Deferiprone tablets (three times a day), 1,000 mg:

Store in the originally supplied bottle, closed tightly to protect from moisture.

Advise patients to take the first dose of deferiprone in the morning, the second dose at midday, and the third dose in the evening. Clinical experience suggests that taking deferiprone with meals may reduce nausea.

Deferiprone tablets, 500 mg:

Store in the originally supplied bottle, closed tightly to protect from moisture.

Advise patients to take the first dose of deferiprone in the morning, the second dose at midday, and the third dose in the evening. Clinical experience suggests that taking deferiprone with meals may reduce nausea.

If a dose of this medicine has been missed, take it as soon as possible. However, if it is almost time for the next dose, skip the missed dose and go back to the regular dosing schedule. Do not catch-up or double doses. …

Warnings & precautions

Do not take this medicine if: Deferiprone is contraindicated in patients with known hypersensitivity to deferiprone or to any of the excipients in the formulations. The following reactions have been reported in association with the administration of deferiprone: Henoch-Schönlein purpura; urticaria; and periorbital edema with skin rash

.

Fatal agranulocytosis can occur with deferiprone use. Deferiprone can also cause neutropenia, which may foreshadow agranulocytosis. Measure the absolute neutrophil count (ANC) before starting deferiprone therapy and monitor it regularly while on therapy

.

Reduction in the frequency of ANC monitoring should be considered on an individual patient basis, according to the health care provider's assessment of the patient's understanding of the risk minimization measures required during therapy.

Interrupt deferiprone therapy if neutropenia develops (ANC < 1.5 × 10

9/L).

Interrupt deferiprone if infection develops and monitor the ANC frequently.

Advise patients taking deferiprone to immediately interrupt therapy and report to their physician if they experience any symptoms indicative of infection.

The incidence of agranulocytosis was 1% of patients in pooled clinical trials of 642 patients with thalassemia syndromes. The mechanism of deferiprone-associated agranulocytosis is unknown. Agranulocytosis and neutropenia usually resolve upon discontinuation of deferiprone, but there have been reports of agranulocytosis leading to death.

Implement a plan to monitor for and to manage agranulocytosis and neutropenia prior to initiating deferiprone treatment.

For agranulocytosis (ANC < 0.2 × 10

9/L) and severe neutropenia (0.2 x 10

9/L ≤ ANC < 0.5 x 10

9/L):

Consider hospitalization and other management as clinically appropriate. …

Deferiprone side effects

The following clinically significant adverse reactions are described below and elsewhere in the labeling:

Agranulocytosis and Neutropenia

Liver Enzyme Elevations

Zinc Deficiency

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The following adverse reaction information represents the pooled data collected from single arm or active-controlled clinical trials with deferiprone tablets (three times a day).

Thalassemia Syndromes

The safety of deferiprone was evaluated in the pooled clinical trial database

. Patients received deferiprone tablets (three times a day). Deferiprone was administered orally three times a day (total daily dose either 50, 75, or 99 mg/kg), N=642. Among 642 patients receiving deferiprone, 492 (76.6%) were exposed for 6 months or longer and 365 (56.9%) were exposed for greater than one year.

The median age of patients who received deferiprone was 19 years (range 1, 77 years); 50.2% female; 71.2% White, 17.8% Asian, 9.2% Unknown, 1.2% Multi-racial and 0.6% Black.

The most serious adverse reaction reported in clinical trials with deferiprone was agranulocytosis

.

The most common adverse reactions (≥6%) reported during clinical trials were nausea, vomiting, abdominal pain, arthralgia, alanine aminotransferase increased and neutropenia. …

Drug interactions

Avoid co-administration of deferiprone with other drugs known to be associated with neutropenia or agranulocytosis. If co-administration is unavoidable, closely monitor the absolute neutrophil count

.

UDP-Glucuronosyltransferases (UGT)

Avoid use of UGT1A6 inhibitors (e.g., diclofenac, probenecid, or silymarin (milk thistle)) with deferiprone

[see

Dosage and Administration (2),

Adverse Reactions (6.1),

Clinical Pharmacology (12.3)]

.

Polyvalent Cations

Deferiprone has the potential to bind polyvalent cations (e.g., iron, aluminum, and zinc); allow at least a 4-hour interval between deferiprone and other medications (e.g., antacids), or supplements containing these polyvalent cations

.

About this medicine

Deferiprone Tablets contain 1,000 mg or 500 mg deferiprone (3-hydroxy-1,2-dimethylpyridin-4-one), a synthetic, orally active, iron-chelating agent. The molecular formula for deferiprone is C

7H

9NO

2and its molecular weight is 139.15 g/mol. Deferiprone has the following structural formula:

Deferiprone is a white to pinkish-white powder. It is sparingly soluble in deionized water (14.3 mg/mL) and has a melting point range of 272°C to 278°C.

Deferiprone Tablets (three times a day), 1,000 mg

White, film-coated, oval shaped tablets; imprinted with "T" score "1 K" on one side and plain on the other. The tablets can be broken in half along the score line. Each tablet contains 1,000 mg deferiprone and the following inactive ingredients: Tablet core - crospovidone, magnesium stearate and methylcellulose; Coating - copovidone, hypromellose, medium chain triglycerides, polydextrose, polyethylene glycol and titanium dioxide. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 58dd1370-5042-833f-e063-6394a90a0777. Read the full official label on DailyMed.